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ABSTRACT
Objectives: To evaluate changes in bone mineral density
(BMD) in the hands, hip and spine after 1 and 2 years of
follow-up, in relation to antirheumatic and antiresorptive
therapies and disease and demographic variables in
patients with recent-onset rheumatoid arthritis (RA).
Methods: Changes in BMD measured in metacarpals 2–4
by digital x-ray radiogrammetry and in the hip and spine by
dual energy x-ray absorptiometry were assessed at baseline
and after 1 and 2 years of follow-up in 218 patients with
recent-onset RA from the BeSt study, who received one of
four treatment strategies: sequential monotherapy (group
1); step-up combination therapy (group 2); initial combina-
tion therapy with tapered high-dose prednisone (group 3); or
initial combination therapy with infliximab (group 4).
Results: After 1 and 2 years, there was significant BMD
loss in all locations, with significantly greater BMD loss in
the hands than generalised BMD loss in the hip and spine.
Initial combination therapy with prednisone or infliximab
were associated with less hand BMD loss compared with
initial monotherapy after 1 and 2 years (20.9 and
21.6%, 20.6 and 21.4%, 21.7 and 23.3%, and 22.6
and 23.6% for group 4–1 after 1 and 2 years, overall
p = 0.001 and p = 0.014, respectively).
Progression in erosions was independently associated
with increased BMD loss both in the hands and hip after
1 year. The use of bisphosphonates protected only
against generalised BMD loss in the hip and spine.
Conclusions: The association between joint damage
progression and both hand and generalised BMD loss in
RA suggests common pathways between these pro-
cesses, with hand BMD loss occurring earlier in the
disease course than generalised BMD loss.
Erosions and hand and generalised bone mineral
density (BMD) loss in rheumatoid arthritis (RA)1–3
results in functional disability and increased risk of
clinical fractures.4–6 Recent studies suggest that
pathophysiological mechanisms of focal erosions
and hand and generalised BMD loss have common
pathways mediated by osteoclasts, in particular by
the receptor activator of nuclear factor-kb ligand.7–9
Clinical studies evaluating BMD in the hands and
generalised BMD in the hip and spine of patients
with early RA showed associations between high
BMD loss and disease severity, as measured by
inflammation parameters, (progressive) joint
damage and functional disability.10–14
In patients with RA, corticosteroids decrease
generalised BMD loss by suppression of inflamma-
tory activity, but as a side-effect, also increase
BMD loss.14–19 Treatment with tumour necrosis
factor a antagonist (anti-TNFa) might protect
against generalised BMD loss.20–22 However, little
is known about the effect of corticosteroids23 and
anti-TNFa21 on hand BMD loss. While the efficacy
of calcium and vitamin D supplements remains
inconclusive, use of bisphosphonates has been
shown to protect against, especially corticoster-
oid-induced, generalised BMD loss.24–28 The influ-
ence of antiresorptive treatment on hand BMD loss
is unclear.29
To investigate the possible common pathological
mechanisms of erosions and hand and generalised
BMD loss and the effects of different antirheu-
matic and antiresorptive treatments on BMD loss,
we assessed the influence of disease-related factors,
antirheumatic treatment strategies and antiresorp-
tive treatments on BMD loss in the hands, hip and
spine after 1 and 2 years of follow-up in patients
with recent-onset, active RA.
METHODS
Patients and therapy
Details of the BeSt study30 and 1-year changes in
generalised BMD loss in the hip and the spine from
this cohort14 have been previously reported. This
study included 218 of 508 patients from eight
investigative centres with analogue hand radio-
graphs and dual energy x-ray absorptiometry
(DEXA) measurements of the hip and the lumbar
spine at baseline and 1 and 2 years follow-up.
Inclusion criteria were diagnosis of RA as defined
by the American College of Rheumatology 1987
revised criteria, symptom duration ,2 years, age
>18 years, and active disease with >6 of 66
swollen joints, >6 of 68 tender joints and either
an erythrocyte sedimentation rate of>28 mm/h or
a visual analogue scale global health of>20 mm on
a scale of 100 mm. Exclusion criteria included
previous treatment with disease-modifying anti-
rheumatic drugs other than antimalarials and
estimated creatinine clearance ,75%. Patients
were randomised to one of the four treatment
strategies: sequential monotherapy (group 1); step-
up combination therapy (group 2); initial combi-
nation therapy with tapered high-dose prednisone
(group 3); or initial combination therapy with
infliximab (group 4). Treatment was adjusted
using 3-monthly calculations of the disease activity
score (DAS, based on a 44 joint count), with
patients progressing to the next treatment step in
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the protocol if DAS .2.4. Calcium supplement (500–1000 mg/
day) was recommended to patients with ,1000 mg/day
calcium intake and vitamin D supplement (cholecalciferol
400 IE/day) to patients with serum vitamin D level below the
local reference value. Antiresorptive therapy with oral alendro-
nate (10 mg/day or 70 mg/week) or risedronate (5 mg/day or
35 mg/week) was advised to non-corticosteroid users with a
BMD T score (22.5 SD in the spine and/or hip and to
corticosteroids users with a T-score (21 SD. The ethics
committee at each participating centre approved the study
protocol and all patients gave written informed consent.
Hand bone mineral density measurements
Standard analogue radiographs of both hands in posteroanterior
position, digitalised by a high-resolution 300 DPI scanner
(Canon Vidar VXR-12 plus), were used to measure BMD by
digital x-ray radiogrammetry (DXR).31 Digital radiographs taken
at baseline and/or during the follow-up period were excluded
from the analyses due to lack of comparability between the
different imaging devices. Mean surrogate hand BMD was
calculated from cortical thickness from regions of interest
measured at the centre of the second, third and fourth
metacarpals through an automated analysis of a standard
projection digital radiograph of the hands using the DXR online
technology (Sectra, Sweden). Hand BMD measured by DXR
seems superior to other BMD measurement devices in detecting
inflammation-related bone loss in patients with arthritis.32–34 To
avoid biasing dominant and non-dominant hands and to
achieve better precision, the mean of both hands was used for
the analyses.
Generalised bone mineral density measurements
BMD measurements of the left total hip and the lumbar spine
L2–L4 posteroanterior view at baseline and 1 and 2 years follow-
up were performed where DEXA was available, using a Hologic
4500 QDR (Hologic, Waltham, Massachusetts, USA) in four
centres and a Lunar DPX (Lunar, Madison, Wisconsin, USA) in
four centres. All procedures were performed in accordance with
the manufacturer’s standardised procedures for hip and spine
BMD measurements. Despite differences between the densit-
ometers, the rates of change in BMD, calculated from serial
measurements assessed for each patient by the same machine,
measurement procedure and references, are comparable.35
Clinical measurements
The following variables were collected at baseline: symptom
duration and serum IgM rheumatoid factor (RF); at baseline and
3-monthly: age, body mass index (BMI), C-reactive protein
(CRP) levels, the use of calcium and vitamin D supplements,
hormone replacement therapy (HRT) and bisphosphonates, and
functional ability as measured by the Dutch validated health
assessment questionnaire (HAQ); and at baseline and after 1 and
2 years of follow-up: menopausal status, age at menopause,
smoking status, alcohol status, previous clinical fractures, osteo-
porosis in first-degree relatives, estimated daily calcium intake and
25(OH)vitamin D levels. The presence of anti-citrullinated protein
Table 1 Baseline demographic and disease characteristics of 218 patients with rheumatoid arthritis
Demographic variables
Sequential monotherapy
(group 1)
(n = 55)
Step-up combination therapy
(group 2)
(n = 46)
Initial combination with
prednisone (group 3)
(n = 65)
Initial combination with
infliximab (group 4)
(n = 52)
Age, years (n = 218)* 55 (13) 54 (14) 55 (14) 54 (15)
Caucasian race, % (n = 218) 95 94 95 94
Women, % (n = 218) 71 83 62 69
Postmenopausal, % (n = 153) 69 62 64 65
Age at menopause, years* 48 (5) 47 (5) 46 (5) 48 (6)
BMI, kg/m2 (n = 216)* 26 (4) 25 (4) 25 (4) 25 (4)
Current smoker, % (n = 218) 47 35 35 27
Cigarettes/day{ 12 (6–23) 10 (10–19) 15 (7–24) 14 (7–18)
Previous clinical fractures .30 years, %
(n = 218)
9 15 17 12
Postmenopausal fractures, % 0 9 8 6
Familial osteoporosis, % (n = 218) 15 15 15 21
Disease-related variables
Symptom duration, weeks (n = 218){ 18 (12–55) 24 (15–41) 22 (13–56) 23 (13–38)
Positive IgM RF, % (n = 218) 64 65 63 62
DAS (n = 218)* 4.6 (0.9) 4.5 (0.9) 4.4 (0.8) 4.2 (0.9)
CRP levels (n = 218){ 29 (10–65) 18 (7–38) 21 (10–61) 33 (7–36)
HAQ score, 0–3 scale (n = 218)* 1.5 (0.7) 1.5 (0.6) 1.4 (0.6) 1.2 (0.7)
Total SHS, 0–448 4.0 (1.3–7.8) 2.8 (1.0–7.5) 3.5 (1.5–7.3) 4.3 (1.0–9.5)
scale (n = 216)*{ 6.0 (6.7) 5.8 (7.7) 4.9 (5.0) 6.2 (6.6)
Total erosions, 0–280 scale*{ 2.0 (1.0–4.0) 1.3 (0.0–4.1) 1.5 (0.5–4.0) 2.5 (0.5–6.8)
3.0 (3.3) 3.2 (4.6) 2.8 (3.4) 4.0 (4.6)
Total JSN, 0–168 scale*{ 1.0 (0.0–4.0) 1.3 (0.0–4.5) 1.5 (0.0–3.3) 1.5 (0.0–3.0)
3.0 (4.2) 2.6 (3.6) 2.1 (2.5) 2.2 (3.0)
Erosive disease, % (n = 216) 77 61 68 69
Calcium intake, mg/day (n = 218)* 875 (337) 889 (369) 930 (326) 881 (350)
25(OH)vitamin D level, nmol/l (n = 175)* 53 (26) 47 (27) 50 (25) 60 (31)
BMI, body mass index; CRP, C-reactive protein; DAS, disease activity score; HAQ, health assessment questionnaire; JSN, joint space narrowing; RF, rheumatoid factor; SHS,
Sharp–van der Heijde score.
*Mean (SD).
{Median (interquartile range).
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antibody was determined from serum samples obtained at baseline
or during follow-up. Disease activity was assessed 3-monthly using
the DAS, based on the erythrocyte sedimentation rate, the number
of swollen joints and the Ritchie articular index for pain in tender
joints in a 44 joint count and the visual analogue scale for patient’s
global assessment of disease activity (0–100 mm, 0 = best and
100 = worst).36 Radiographic joint damage was assessed using the
Sharp–van der Heijde score (SHS), scored after 1 and 2 years of
follow-up by two independent physicians blinded for patient-level
data and treatment assignment. After 1 year, the intra-observer
coefficients were 0.93 and 0.94, and the interobserver coefficient
was 0.93. Erosive disease at baseline was defined as erosion score
.0.5. Progression of joint damage after 1 year was defined as
progression greater than the smallest detectable change (SDC),
calculated as 4.18 points in the first year of follow-up.
Statistical analysis
All analyses were performed in an intention-to-treat method
using all available data. Changes in BMD were expressed as
changes at 1 and 2 years follow-up in absolute BMD values
compared with baseline BMD in percentages. Non-parametric
tests were performed to compare the median percentages of
BMD loss in the hands, hip and spine between the treatment
strategies. The p-values derived by these tests were corrected for
multiple comparisons by the step-down Bonferroni–Holmes
adjustment. Multivariate regression analyses, adjusted for the
use of bisphosphonates, vitamin D and calcium supplements,
HRT and intra-articular steroids and changes in DAS, HAQ and
SHS during follow-up, were used to compare the treatment
strategies, independently of differences in antiresorptive treat-
ment and disease activity between the groups. Association
among disease-related variables and changes in BMD in the
different measurement sites were analysed by univariate
regression analysis. Potential independent predictors of BMD
loss were evaluated by stepwise multivariate regression analyses
performed as forward (conditional) procedures, adjusted for
treatment group. All tests were two-tailed and p(0.05 was
considered statistically significant.
RESULTS
Patient characteristics
In 218 patients BMD measurements in the hands, lumbar spine
and total left hip were performed at baseline and 1 and 2 years
follow-up. In 27 patients no hand BMD measurements were
performed after 1 or 2 years due to logistic reasons and in 20
patients no BMD in the hip or spine measurements after 1 or
2 years were performed due to logistic reasons and in two cases
due to bilateral hip prosthesis.
The baseline demographic and disease variables were not
significantly different between the four treatment groups
(table 1) or with the rest of the BeSt study population
(n = 290) (data not shown). The majority of patients were
middle-aged, postmenopausal women with recent-onset RA
with median symptom duration of 23 weeks. All patients had
active disease with a mean (SD) DAS of 4.4 (0.9), 69% of
patients had erosive disease at baseline and 58% of patients were
anti-citrullinated protein antibody positive at baseline or during
follow-up.
Osteoporosis treatment
The use of osteoporosis treatment during the follow-up is
summarised in table 2. Of patients advised to take bispho-
sphonates, only 45% were actually prescribed oral bispho-
sphonates, of which 66% received alendronate and 34% received
risedronate. Thirty-nine per cent of patients with low calcium
intake received calcium supplement, and 40% of patients with
25(OH)vitamin D levels below the reference value received
vitamin D supplement during the 2 years of follow-up. Forty-
five per cent of the patients taking calcium and vitamin D
supplements were also taking bisphosphonates.
Bisphosphonates were prescribed to significantly more patients
in group 3 (initial combination therapy including prednisone)
than in the other groups (29% vs 4–9%, overall p,0.0001, and
32% vs 15–17%, overall p = 0.05 during the first year and first
2 years of follow-up, respectively); and more patients in group 3
used calcium supplements (43% vs 19–20%, overall p = 0.005
and 46% vs 22–31%, overall p = 0.039, respectively). There was
Table 2 Osteoporosis treatment during first year and first 2 years of follow-up of 218 patients with rheumatoid arthritis
Sequential monotherapy (group 1)
(n = 55)
Step-up combination
therapy (group 2)
(n = 46)
Initial combination with
prednisone (group 3)
(n = 65)
Initial combination with
infliximab (group 4)
(n = 52)
Bisphosphonates use, % (n = 218) 7 9 29 4
15 17 32 15
No. of months used during follow-up* 9 (7–11) 8 (4–9) 9 (6–9) 9 (6–12)
11 (7–12) 12 (5–12) 10 (9–12) 9 (6–12)
Calcium supplements, % (n = 218) 20 20 43 19
22 30 46 31
No. of months used during follow-up* 9 (6–12) 9 (2–11) 9 (8–11) 9 (8–12)
12 (12–12) 12 (11–12) 12 (6–12) 12 (10–12)
Vitamin D supplements, % (n = 218) 6 15 22 10
11 22 22 12
No. of months used during follow-up* 6 (6–12) 9 (6–9) 9 (5–9) 9 (8–11)
6 (3–12) 12 (11–12) 12 (8–12) 12 (11–12)
HRT use, % (n = 213) 15 15 8 15
15 14 8 19
No. of years used* 9 (3–17) 15 (2–19) 5 (4–17) 6 (2–16)
9 (4–19) 14 (4–21) 7 (5–19) 7 (2–16)
Intra-articular steroids injections 33 17 8 10
(min 1–max 6), % (n = 218) 13 4 12 6
HRT, hormone replacement therapy.
*Median (interquartile range).
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a trend for increased vitamin D supplements use by patients in
group 3 during the first year of follow-up (22% vs 6–15%,
overall p = 0.057). More patients received intra-articular steroid
injections in groups 1 and 2 than in groups 3 and 4 during the
first year of follow-up (overall p = 0.001).
Changes in hand and generalised bone mineral density loss
After 1 year of treatment, the median (IQR) change from
baseline in hand BMD was approximately 21.4% (23.6% to
0.1%; p,0.0001) in the hands compared with 20.9% (22.9% to
1.7%; p,0.0001) in generalised BMD in the hip and 20.5%
(22.8% to 1.5%; p,0.0001) in the spine. Hand BMD loss was
significantly greater than generalised BMD loss after 1 year
(hand versus hip p = 0.004, hand versus spine p,0.0001, hip
versus spine p = 0.43).
After 2 years of treatment, the median (IQR) change in BMD
was approximately 22.5% (26.0% to 20.2%; p,0.0001) in the
hands compared with 20.5% (22.8% to 2.1%; p,0.0001) in the
hip and 21.0% (23.9% to 1.6%; p,0.0001) in the spine. Hand
BMD loss remained significantly greater than generalised BMD
loss (hand versus hip and spine p,0.0001, hip versus spine
p = 0.46).
Effect of treatment strategies on bone mineral density changes
In univariate analyses, patients in the initial monotherapy
strategy (group 1) had significantly more BMD loss in the hands
after 1 year than patients in the initial combination therapies
(groups 3 and 4) (22.6, 21.7, 20.6 and 20.9% for group 1–4,
respectively, overall p = 0.001, group 1 versus 3 p = 0.000, group
1 versus 4 p = 0.021, group 2 versus 3 p = 0.038, group 2 versus 4
p = 0.101, table 3).
Multivariate regression analyses, adjusted for differences in
use of antiresorptives between the treatment strategies during
follow-up, also showed significant less BMD loss in the hands in
the initial combination therapies (data not shown).
The amount of BMD loss in the hands was associated with
disease severity (fig 1). Multivariate regression analyses,
adjusted for differences in antiresorptives and changes in disease
activity (DAS, HAQ and SHS after 1 year) between the groups,
showed no significant differences in hand BMD loss between
the treatment strategies anymore (data not shown). Differences
in hand BMD loss between the treatment groups remained
significant after 2 years of treatment in univariate analyses
(23.6, 23.3, 21.4 and 21.6% for groups 1–4, respectively,
overall p = 0.014, group 1 vs 3 p = 0.009, group 1 vs 4 p = 0.033,
group 2 vs 3 p = 0.204, group 2 vs 4 p = 0.216). However, after
correction for disease activity and use of antiresorptives, hand
BMD loss was again no longer statistically significant between
the treatment groups (data not shown). There were no
statistically significant differences between the four treatment
groups in generalised BMD loss in the hip (overall p = 0.42 and
p = 0.52 after 1 and 2 years of follow-up, respectively) and the
spine (overall p = 0.52 and p = 0.93, respectively).14
Given the dynamics of DAS-directed treatment adjustments
in all four treatment groups, patients who started treatment
with prednisone (group 3) were eligible for discontinuation of
that drug after at least 28 weeks (at 2 years, 82% had
Table 3 Median (IQR) BMD change in the hands, hip and spine, in percentages of baseline, in the four
treatment groups after 1 and 2 years of follow-up
Sequential
monotherapy
(group 1)
Step-up combination
therapy (group 2)
Initial combination
with prednisone
(group 3)
Initial combination
with infliximab
(group 4)
BMD loss in hands
After 1 year 22.6 (25.4 to 20.8) 21.7 (25.1 to 20.1) 20.6 (22.2 to 0.3) 20.9 (22.8 to 0.5)
After 2 years 23.6 (26.8 to 21.4) 23.3 (26.8 to 20.2) 21.4 (25.4 to 20.1) 21.6 (24.7 to 0.3)
BMD loss in hip
After 1 year 21.6 (23.5 to 1.1) 20.4 (22.7 to 2.3) 21.0 (24.6 to 1.7) 20.6 (22.7 to 2.1)
After 2 years 21.1 (22.9 to 2.0) 20.2 (22.6 to 2.3) 20.2 (22.6 to 3.2) 20.6 (23.3 to 2.0)
BMD loss in spine
After 1 year 20.2 (22.8 to 2.0) 21.1 (22.5 to 1.4) 21.0 (22.7 to 1.8) 20.1 (23.1 to 1.1)
After 2 years 20.4 (24.6 to 2.6) 21.6 (24.6 to 1.1) 20.5 (23.9 to 2.1) 21.0 (23.3 to 1.4)
BMD, bone mineral density.
Figure 1 The mean hand bone mineral density (BMD) loss (in
percentages from baseline) and Sharp–van der Heijde (SHS) erosion
score increase (points) according to the four treatment groups. Hand
BMD: bone mineral density in the hands measured by digital x-ray
radiogrammetry. After 1 year of follow-up, significant differences in
increase in SHS erosion score between the four treatment groups: 1 vs 3
(p = 0.038), 1 vs 4 (p = 0.023), 2 vs 3 (p = 0.030), 2 vs 4 (p = 0.018)
and significant differences in BMD loss in the hands between the four
treatment groups: 1 vs 3 (p = 0.000), 1 vs 4 (p = 0.021), 2 vs 3
(p = 0.038), 2 vs 4 (p = 0.101). After 2 years of follow-up, significant
differences in changes in the SHS erosion score between the four
treatment groups: 1 vs 3 (p = 0.001), 1 vs 4 (p = 0.001), 2 vs 3
(p = 0.072), 2 vs 4 (p = 0.080) and significant differences in BMD loss in
the hands between the four treatment groups: 1 vs 3 (p = 0.009), 1 vs 4
(p = 0.033), 2 vs 3 (p = 0.204), 2 vs 4 (p = 0.216).
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discontinued prednisone due to a good response or failure to
respond), whereas patients who did not respond to previous
disease-modifying anti-rheumatic drug therapy in groups 2 (step
up to combination therapy) and 4 (initial combination therapy
with infliximab) were allowed to begin prednisone starting at
12 and 15 months, respectively. In the patients who used
prednisone in all groups, the mean (SD) cumulative dose was
2428 (388) mg and 2796 (1197) mg per patient during the first
year and first 2 years of follow-up, respectively. Subanalyses
adjusted for differences in disease activity and anti-osteoporotic
treatment in multivariate analyses showed no differences in
hand or generalised BMD loss after 1 year between patients
exposed to and naive to prednisone (data not shown). In the
second year of follow-up, patients who did not respond to
previous disease-modifying anti-rheumatic drug therapy in
groups 1–3 were allowed to receive infliximab. The mean (SD)
cumulative dose of infliximab in all groups was 29.5 (8.5) mg/kg
and 37.0 (21.9) mg/kg per patient during the first year and the
first 2 years of follow-up, respectively. There were no differ-
ences in hand or generalised BMD loss after 1 and 2 years
between patients exposed to and naive to infliximab (data not
shown).
Determinants of bone mineral density loss
Univariate linear regression analyses showed that higher age,
postmenopausal status and current smoking status were
associated with greater hand BMD loss after 1 year (table 4),
but demographic variables were not associated with generalised
BMD loss in the hip or spine. Of disease-related variables,
progression in erosion scores greater than the SDC was
associated with increased BMD loss both in the hands and hip
after 1 year of follow-up. Further, higher CRP levels at baseline
and a lower decrease in CRP levels after 1 year and higher HAQ
scores at baseline were associated with increased BMD loss in
the hands and higher erosion scores at baseline with increased
BMD loss in the hip. There was a trend of increased hand BMD
loss in patients who were positive for RF after 1 year (p = 0.055).
The use of bisphosphonates, calcium and vitamin D supplements
was associated with reduced generalised BMD loss.
Multivariate regression analyses showed that postmenopau-
sal status was an independent risk factor of BMD loss in the
hands (table 5). Increase in erosion score after 1 year was
associated with both greater hand and generalised BMD loss in
the hip. Higher CRP levels at baseline were independently
associated with increased hand BMD loss. The use of bispho-
sphonates was independently associated with reduced general-
ised BMD loss in both the hip and spine.
DISCUSSION
In this large longitudinal study we compared changes in hand
BMD, measured by DXR, with changes in generalised BMD in
the hip and the spine, measured by DEXA, in 218 patients with
recent-onset RA after 1 and 2 years of DAS-steered treatment in
the BeSt trial. There are several important findings. Hand BMD
loss was greater than generalised BMD loss in the hip and spine.
Patients treated with initial combination therapy with tapered
high-dose corticosteroids or anti-TNFa infliximab had less hand
BMD loss due to better suppression of inflammation. Both hand
and generalised BMD loss were associated with progression of
radiographic destruction. Bisphosphonates protected only
against generalised BMD loss.
In Caucasian populations, the rate of BMD loss in the
metacarpals has been found to be about 21.2 to 21.5% per year
after the menopause.37 In our population, BMD loss was
approximately 22.3% after 1 year and 24.4% after 2 years in
postmenopausal women, indicating that postmenopausal
patients with recent-onset RA may experience a twofold
increase in BMD loss in the hands per year, despite aggressive
Table 4 Demographic and disease factors associated with BMD loss in the hands, hip and spine after 1 year, derived by univariate regression
analyses
Variable
BMD loss in hands BMD loss in hip BMD loss in spine
b coefficient p Value b coefficient p Value b coefficient p Value
Age, years 20.068 0.002 20.032 0.19 0.012 0.56
Female gender 0.26 0.71 0.55 0.46 20.37 0.55
Postmenopausal status 23.26 0.000 20.67 0.43 20.30 0.68
Smoking status 21.43 0.027 0.801 0.26 0.29 0.62
BMI, kg/m2 at baseline 0.003 0.97 0.14 0.13 20.028 0.71
Duration complaints before
inclusion, weeks
0.002 0.70 0.006 0.19 0.005 0.19
ACPA positive 20.376 0.55 0.053 0.94 0.721 0.22
RF positive 21.24 0.055 20.050 0.94 0.53 0.37
DAS at baseline 20.068 0.85 20.18 0.67 0.062 0.85
DDAS 0–1 year 20.26 0.33 20.23 0.45 0.16 0.52
CRP at baseline 20.028 0.000 0.004 0.636 20.008 0.290
DCRP 0–1 year 0.032 0.002 20.004 0.679 0.008 0.388
HAQ at baseline 21.12 0.036 20.079 0.13 0.60 0.16
DHAQ 0–1 year 20.42 0.36 20.44 0.37 0.062 0.88
Erosions at baseline 20.046 0.56 20.20 0.015 0.035 0.62
JSN at baseline 20.057 0.57 20.035 0.70 20.037 0.66
DErosions 0–1 year 20.16 0.012 20.20 0.003 20.044 0.44
DJSN 0–1 year 20.046 0.37 20.055 0.34 20.024 0.62
BP use 0–1 year 0.14 0.89 2.58 0.008 4.02 0.000
Calcium supplement 0–1 year 20.060 0.93 1.59 0.037 1.56 0.015
Vitamin D supplement 0–1 year 0.32 0.73 1.91 0.052 1.62 0.048
HRT use 0–1 year 0.56 0.53 21.02 0.31 20.19 0.82
ACPA, anti-citrullinated protein antibody; BMI, body mass index; RF, rheumatoid factor; DAS, disease activity score; CRP, C-reactive protein; HAQ, health assessment questionnaire;
JSN, joint space narrowing; BP, bisphosphonates; HRT, hormone replacement therapy.
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suppression of inflammation by DAS-directed treatment.
However, comparisons should be interpreted with caution due
to possible demographic differences between populations.
BMD loss in the hands is common in recent-onset RA,
whereas generalised BMD loss primarily occurs during a later
course of the disease.38 39 Despite significant reduction in disease
activity over the treatment period, BMD loss in the hands was
on average two to three times more severe than generalised
BMD loss in the hip or spine in our patients. The majority of
our patients with hand BMD loss had no generalised BMD loss
in the hip (72%) and spine (80%) during 2 years of follow-up.
We found significantly more BMD loss after 1 and 2 years in
the hands than in the hip and spine. There are several possible
explanations for this finding. First, two different techniques
were used to measure different components of the bone: DXR
estimates cortical BMD loss and DEXA measures both cortical
and trabecular BMD loss. This might indicate that the cortical
barrier of bone is more exposed to inflammation-induced
osteoclasts activation than the trabecular site. However,
previous studies studying BMD loss in the hands by DEXA,
the gold standard for bone assessment, also reported more
severe hand BMD loss compared with generalised BMD loss in
patients with RA.40–42 Second, greater changes in BMD in the
hands, measured by DXR, than in generalised BMD loss,
measured by DEXA, may be due to the higher precision of the
DXR technique and the averaging of three bones in one hand
and the averaging of both hands.31 As a result, DXR may be
more sensitive in tracing changes in BMD loss than DEXA.
Third, the process of hand BMD loss may be more sensitive to
or more directly influenced by cytokine stimulation originating
in adjacent inflamed synovial tissue compared with the process
of generalised BMD loss at locations with undetected local
inflammation. Fourth, hand BMD loss that is more severe and
difficult to suppress may be a reflection of ongoing inflamma-
tion that remains undetected by clinical observation. Previously,
Brown et al showed synovitis detected with magnetic resonance
imaging in patients with RA in clinical remission.43 Lastly, the
protective effect of bisphosphonates was only observed against
generalised, and not hand, BMD loss. A previous study showed
that bisphosphonates were effective against hand BMD loss in
patients without RA.29 To our knowledge, this is the first study
measuring the effect of antiresorptive treatment on hand BMD
loss in patients with recent-onset RA. A possible explanation for
the conflicting results is that the inflammation nearby the
metacarpals may counteract the antiresorptive effect of bispho-
sphonates due to high resorptive activity of the osteoclasts. A
limitation to our study is that the guidelines for anti-osteoporotic
treatment in patients who were osteopenic and osteoporotic were
poorly implemented: only 45% of patients requiring bispho-
sphonates were actually prescribed bisphosphonates during the
2 years of follow-up. However, despite the low prescription, the
use of bisphosphonates protected against generalised BMD loss.
We found significantly less hand BMD loss in the initial
combination group with high-dose prednisone compared with
the initial monotherapy groups. In a previous double-blind
study comparing oral prednisolone 7.5 mg/day for 2 years with
placebo in patients with early RA, the prednisone group had less
hand BMD loss measured by DXR after 1 and 2 years.23 This
suggests that the benefits from quick effective suppression of
disease activity with corticosteroids exceed the direct negative
influence on hand BMD. We did not find differences in changes
in BMD in the hip and the spine after 1 and 2 years follow-up
between the initial group with prednisone and the other
treatment groups.14 17
In our study, patients who received initial combination
therapy with infliximab had significantly less hand BMD loss
than patients who received conventional therapy in groups 1
and 2 after 1 year, but there were no differences in generalised
BMD loss. In a group of 102 patients with RA with a disease
duration of 1–49 years, Vis et al showed consistent BMD in the
spine and hip but significant BMD loss in the hands (20.8%)
after 1 year of treatment with infliximab.21 However, compar-
isons should be interpreted with caution due to differences in
demographic and RA-related variables between the two
populations, such as use of antiresorptives and shorter disease
duration in our population, which is associated with more rapid
hand BMD loss.44
The independent associations between focal erosions and
hand and generalised BMD loss support the current under-
standing that these three processes share common pathways
mediated by the cellular action of osteoclasts.7 45 46 BMD loss
involves elevated bone loss in the hands in the early course of
the disease and generalised BMD loss often during a later phase
of RA.
In conclusion, in patients with recent-onset RA, the suppres-
sion of inflammation with effective treatment strategies is
essential for bone preservation. The association between
progressive erosive disease and high hand and generalised
BMD loss indicates common pathophysiological mechanisms,
hand BMD loss occurring more often in the early phase of the
disease than generalised BMD loss. Identifying therapeutic
opportunities to prevent or treat all these forms of bone loss in
patients with RA remains a challenge.
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